CPT2 and cancer: Overall, our data suggest that [C16Pyr][Amp] impairs the hallmark of cancer related to the reprogramming of cellular energy and metabolism [76], decreasing both CPT2 (in PCa cell lines) and LDHA (in BrCa cell lines) expression, which affects the energy supply by FAO and the lactate production during glycolysis, respectively.